Topical emollient study adds to barrier-care case in canine AD

A new clinical trial in Veterinary Dermatology suggests a novel once-daily topical “emollient plus” may help dogs with controlled, nonseasonal canine atopic dermatitis. In the 30-day proof-of-concept study, 21 client-owned dogs received an in-house formulation, and investigators reported statistically significant reductions in both pruritus and lesion scores. Mean pVAS10 scores fell from 4.25 to 3.38, and mean CADESI-04 scores dropped from 24.62 to 13.43. The study also found significant reductions in transepidermal water loss and skin pH at the pinnae, and 90.47% of pet parents rated treatment efficacy as good to excellent. The authors said the product showed a favorable safety profile, but noted that controlled studies are still needed. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the findings add to a growing body of evidence that skin-barrier support may have a meaningful adjunctive role in canine atopic dermatitis management. The updated ICADA definition emphasizes that canine atopic dermatitis involves not just inflammation, but also skin-barrier abnormalities and microbial dysbiosis, which helps explain continued interest in barrier-targeted topicals. Earlier studies have likewise suggested benefit when topical barrier therapies are layered onto standard care, including longer remission when weekly topical therapy was combined with lokivetmab. Still, this latest trial was small, uncontrolled, and tied to a formulation the authors say may be commercialized in the future, so it’s best read as an early signal rather than practice-changing evidence. (pmc.ncbi.nlm.nih.gov)

What to watch: Watch for a randomized, controlled follow-up study, and for any licensing or commercialization moves tied to the trade-secret formulation described by the authors. (pubmed.ncbi.nlm.nih.gov)